In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taxus Cardium Pharmaceuticals Group Inc.

www.cardiumthx.com

Latest From Taxus Cardium Pharmaceuticals Group Inc.

Venture Funding Deals, August 2016

Derived from Strategic Transactions, Informa's premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced June through July 2016.

Commercial Business Strategies

Deals Shaping the Medical Industry, August 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in July 2016.

Market Intelligence Deals

Venture Funding Deals, June 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced April through May 2015.

BioPharmaceutical Medical Device

BioNotebook: First trial for Bellicum's CAR T cell safety switch; deals, trials, financings

NCI study uses Bellicum's CAR T cell safety switch; Innocutis licenses Sitavig from BioAlliance; Portola initiates andexanet alfa Phase III; Alcobra enrolls first Phase III patient; Cardium becomes Taxus Cardium; Sangamo prices $100m offering; Alexza completes $45m private placement; and Oxygen raising $52m.

Infectious Diseases Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Cardium Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Taxus Cardium Pharmaceuticals Group Inc.
  • Senior Management
  • Christopher J Reinhard, Chmn., Pres. & CEO
    Gabor M Rubanyi, MD, PhD, CSO
  • Contact Info
  • Taxus Cardium Pharmaceuticals Group Inc.
    Phone: (858) 436-1000
    11750 Sorrento Valley Rd., Ste. 250
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register